Will expanded ART use reduce the burden of HIV-associated chronic lung disease?

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 27-33

  Kunisaki, Ken M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

antiretroviral therapy; chronic obstructive; highly active; HIV; pulmonary disease

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 84892374129     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000018     Document Type: Review

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860
2. Sogaard OS, Lohse N, Gerstoft J, et al. Mortality after hospitalization for pneumonia among individuals with HIV, 1995-2008: A Danish cohort study. PLoS One 2009; 2008: 2009; 4: E7022
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study. Lancet 2012; 380: 2095-2128
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1999-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196
5. Niewoehner DE. Clinical practice. Outpatient management of severe COPD. N Engl J Med 2010; 362: 1407-1416
6. Kerstjens HA, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: Facts, figures, and fallacies. Thorax 1997; 52: 820-827
7. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679
8. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648
9. Centers for Disease Control and Prevention (CDC). HIV Surveillance Report 2010. Atlanta, Georgia: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services; 2012; 22
10. Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among injection drug users: A prospective cohort. AIDS 2013; 27: 1303-1311
11. George MP, Kannass M, Huang L, et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009; 4: E6328
12. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010; 182: 790-796
13. Cui Q, Carruthers S, McIvor A, et al. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: A cross-sectional study. AIDS Res Ther 2010; 7: 6
14. Madeddu G, Fois AG, Calia GM, et al. Chronic obstructive pulmonary disease: An emerging comorbidity in HIV-infected patients in the HAART erä Infection 2013; 41: 347-353
15. Hirani A, Cavallazzi R, Vasu T, et al. Prevalence of obstructive lung disease in HIV population: A cross sectional study. Respir Med 2011; 105: 1655-1661
16. Kristoffersen US, Lebech AM, Mortensen J, et al. Changes in lung function of HIV-infected patients: A 4.5-year follow-up study. Clin Physiol Funct Imaging 2012; 32: 288-295
17. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505
18. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005; 142: 233-239
19. Niaura R, Shadel WG, Morrow K, et al. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000; 31: 808-812
20. Drach L, Holbert T, Maher J, et al. Integrating smoking cessation into HIV care. AIDS Patient Care STDs 2010; 24: 139-140
21. Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIVpositive compared to HIV-negative veterans. Chest 2006; 130: 1326-1333
22. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183: 388-395
23. Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Serv Res 2011; 11: Doi 10.1186/1472-6963-11-37
24. Lacasse Y, Daigle JM, Martin S, Maltais F. Validity of chronic obstructive pulmonary disease diagnoses in a large administrative database. Can Respir J 2012; 19: E5-e9
25. Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax 2012; 67: 309-314
26. Morris AM, Huang L, Bacchetti P, et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000; 162: 612-616
27. Morris A, Kingsley LA, Groner G, et al. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 2004; 18: 793-798
28. Huang L, Crothers K, Morris A, et al. Pneumocystis colonization in HIVinfected patients. J Eukaryot Microbiol 2003; (50 Suppl): 616-617
29. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170: 408-413
30. Lozupone C, Cota-Gomez A, Palmer BE, et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med 2013; 187: 1110-1117
31. Global Initiative for Chronic Obstructive Lung, Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated, 2013
32. Barnes PJ, Shapiro S D, Pauwels R A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688
33. Guillon JM, Autran B, Denis M, et al. Human immunodeficiency virus-related lymphocytic alveolitis. Chest 1988; 94: 1264-1270
34. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 159 (5 Pt 1): 1439-1444
35. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795
36. Bjerk SM, Baker JV, Emery S, et al. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: A case-control study. PLoS One 2013; 8: E56249
37. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: E203
38. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-Analysis. Thorax 2004; 59: 574-580
39. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255
40. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353-2361
41. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 2: 1294-1298
42. Wanchu A, Rana SV, Pallikkuth S, Sachdeva RK. Short communication: Oxidative stress in HIV-infected individuals: A cross-sectional study. AIDS Res Hum Retroviruses 2009; 25: 1307-1311
43. Moriarty SE, Shah JH, Lynn M, et al. Oxidation of glutathione and cysteine in human plasma associated with smoking. Free Radic BiolMed 2003; 35: 1582-1588
44. Lassiter C, Fan X, Joshi PC, et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 2009; 6: 1
45. Twigg HL, Weiden M, Valentine F, et al. Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 2008; 197: 109-116
46. Twigg HL, Knox KS. Impact of antiretroviral therapy on lung immunology and inflammation. Clin Chest Med 2013; 34: 155-164
47. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) study. Clin Trials 2013; 10 (1 Suppl): S5-S36